학술논문

The Utility of Exercise Testing in Patients with Lung Cancer
Document Type
article
Source
Journal of Thoracic Oncology. 11(9)
Subject
Biomedical and Clinical Sciences
Clinical Sciences
Oncology and Carcinogenesis
Clinical Research
Prevention
Lung
Patient Safety
Lung Cancer
Cancer
4.2 Evaluation of markers and technologies
Detection
screening and diagnosis
Respiratory
Good Health and Well Being
Exercise Test
Humans
Lung Neoplasms
Oxygen Consumption
Physical Education and Training
Pneumonectomy
Prognosis
Risk Assessment
Exercise testing
Cardiopulmonary exercise testing
Six-minute walk test
Stair-climbing test
Shuttle walk test
Lung cancer
Cardiorespiratory Medicine and Haematology
Oncology & Carcinogenesis
Clinical sciences
Oncology and carcinogenesis
Language
Abstract
The harm associated with lung cancer treatment include perioperative morbidity and mortality and therapy-induced toxicities in various organs, including the heart and lungs. Optimal treatment therefore entails a need for risk assessment to weigh the probabilities of benefits versus harm. Exercise testing offers an opportunity to evaluate a patient's physical fitness/exercise capacity objectively. In lung cancer, it is most often used to risk-stratify patients undergoing evaluation for lung cancer resection. In recent years, its use outside this context has been described, including in nonsurgical candidates and lung cancer survivors. In this article we review the physiology of exercise testing and lung cancer. Then, we assess the utility of exercise testing in patients with lung cancer in four contexts (preoperative evaluation for lung cancer resection, after lung cancer resection, lung cancer prognosis, and assessment of efficiency of exercise training programs) after systematically identifying original studies involving the most common forms of exercise tests in this patient population: laboratory cardiopulmonary exercise testing and simple field testing with the 6-minute walk test, shuttle walk test, and/or stair-climbing test. Lastly, we propose a conceptual framework for risk assessment of patients with lung cancer who are being considered for therapy and identify areas for further studies in this patient population.